The SRRM4 gene has been recently identified as a key protein responsible for a subtype of highly aggressive prostate cancers, called neuroendocrine prostate cancer (NEPC). Detection of SRRM4 protein in patient tumor biopsies is therefore important to predict and diagnose NEPC, so that early and more effective therapeutic means can be in place. Unfortunately, there […]

Unprecedented advances have been made in the treatment of cancer through the use of antibody against immune checkpoints, priming immune system instead of targeting cancer, with approval of several antibodies for multiple cancer types. However, so far we are merely seeing the tip of the iceberg because responses to this form of therapy are not […]

Targeted cancer therapies have significantly improved the treatment of leukemias, but emergence of treatment resistance and subsequent cancer relapse significantly reduces patient survival. This relapse is primarily caused by the inability of current therapies to eradicate leukemic stem cells. It is currently extremely challenging to study these stem cells, due to its rarity in patient […]

Bladder Carcinoma (BC) is the fifth most common cancer in Canada. Although most individuals have surgery to remove BC tumors, the risk of another BC developing and/or progressing to invasive disease is high so long-term surveillance is necessary. The current method for screening for BC is not sensitive enough, and individuals often end up undergoing […]